773 related articles for article (PubMed ID: 26672084)
1. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
2. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
5. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
7. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
8. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
11. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
12. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Stinchcombe TE
Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
15. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
20. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]